FDA clears way for U.S. trials of Alcobra ADHD therapy

|About: Alcobra Ltd. (ADHD)|By:, SA News Editor

Alcobra (ADHD) will be able to start U.S. trials of its Metadoxine Extended Release (MDX) treatment for Attention Deficit Hyperactivity Disorder (ADHD), Fragile X Syndrome and other cognitive dysfunctions after the FDA approved the company's Investigational New Drug (IND) application for the treatment.

Alcobra expects to soon start enrolling adult patients in a Phase III trial of MDX. (PR)